Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 3/20 | 0.33 |
| ▸ | TACR2 | P21452 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | NPY4R | P50391 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20677165 | 0.88 | TACR1 (0.32) | — | |
| Trifluoroacetic Acid SCHEMBL31064901 | 0.72 | CA2 (0.34) | KIF11MEN1KMT2ANPY1RTACR2 | |
| Trifluoroacetic Acid SCHEMBL20263649 | 0.71 | PKM (0.41) | KIF11NPY1RCA2NPY4RADORA2A | |
| Trifluoroacetic Acid SCHEMBL28645461 | 0.69 | PKM (0.41) | NPY1RCA2NPY4RADORA2AADORA1 | |
| Trifluoroacetic Acid SCHEMBL29467754 | 0.69 | MGLL (0.40) | NPY1RCA2NPY4RADORA2AADORA1 | |
| SCHEMBL28388883 | 0.68 | MGLL (0.36) | — | |
| SCHEMBL31031977 | 0.68 | MEN1 (0.38) | MEN1KMT2ATACR2TLR2CA2 | |
| SCHEMBL24797605 | 0.67 | MGLL (0.42) | MEN1KMT2ACA2 | |
| SCHEMBL24798072 | 0.67 | MGLL (0.42) | MEN1KMT2ACA2 | |
| SCHEMBL17841834 | 0.67 | MGLL (0.42) | MEN1KMT2ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3432934-A1 | PRODRUGS OF CYTOTOXIC ACTIVE AGENTS HAVING ENZYMATICALLY CLEAVABLE GROUPS | Bayer Pharma Aktiengesellschaft (DE) | 2019-01-30 | — | — | EP | disclosed |